Prior Stephen David
SEC insider (Form 3/4/5 filer). CIK 0002042268. Chief Strategy Officer at AN2 Therapeutics, Inc. (ANTX). 6 reported Form 4/5 transactions since Sep 2024; latest on Jan 6, 2026. Located in MENLO PARK, CA.
Companies Prior Stephen David has filed insider reports for
- AN2 Therapeutics, Inc. (ANTX): Officer, Chief Strategy Officer
Prior Stephen David
CIK: 0002042268
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)4 (66.7%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (33.3%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ANTX
AN2 Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jan 6, 2026ANTX
AN2 Therapeutics, Inc.
SaleDirect2.9K shares at avg. $1.01$3K - Jan 5, 2026ANTX
AN2 Therapeutics, Inc.
SaleDirect3.6K shares at avg. $1.00$4K - Nov 4, 2025ANTX
AN2 Therapeutics, Inc.
SaleDirect765 shares at avg. $1.14$872.1 - Feb 26, 2025ANTX
AN2 Therapeutics, Inc.
AwardDirect28K shares- - Jan 3, 2025ANTX
AN2 Therapeutics, Inc.
SaleDirect2K shares at avg. $1.34$3K - Nov 4, 2024ANTX
AN2 Therapeutics, Inc.
AwardDirect10.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 6, 2026 | ANTX AN2 Therapeutics, Inc. | Sale | 2,858 | $1.01 | $2,892 | Direct |
| Jan 5, 2026 | ANTX AN2 Therapeutics, Inc. | Sale | 3,604 | $1.00 | $3,615 | Direct |
| Nov 4, 2025 | ANTX AN2 Therapeutics, Inc. | Sale | 765 | $1.14 | $872 | Direct |
| Feb 26, 2025 | ANTX AN2 Therapeutics, Inc. | Award | 28,000 | - | - | Direct |
| Jan 3, 2025 | ANTX AN2 Therapeutics, Inc. | Sale | 2,029 | $1.34 | $2,721 | Direct |
| Nov 4, 2024 | ANTX AN2 Therapeutics, Inc. | Award | 10,125 | - | $0 | Direct |
1-6 of 6 transactions